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Postoperative nausea and vomiting (PONV) is a common, distressing complica-
tion after anesthesia and surgery, with an overall incidence of 30-70% after
general anesthesia.
1 Most (54-92%) patients undergoing gynecological
laparoscopic surgery with general anesthesia experience PONV,
2 justifying the
use of prophylactic antiemetics. Selective serotonin [5-hydroxytryptamine (5-
HT)] subtype 3 (5-HT3) receptor antagonists can safely and effectively prevent
PONV. Indeed, PONV guidelines include the use of 5-HT3 receptor antagonists as
the first-line preventive agents in high-risk patients.
3
Ondansetron, a selective 5-HT3 receptor antagonist, has prophylactic antiemetic
effects after a single administration before or after surgery.
4 Azasetron, a selective
potent 5-HT3 receptor antagonist, is a derivative of benzamide with chemical
structure different from other 5-HT3 receptor antagonists such as granisetron,
ondansetron, ramosetron and tropisetron.
5 Azasetron has a longer duration of
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Purpose: We compared the prophylactic effects of intravenously administered azasetron (10 mg) and ondansetron
(8 mg) on postoperative nausea and vomiting (PONV) in patients undergoing gynecological laparoscopic surgery
under general anesthesia. Materials and Methods: We studied 98 ASA physical status I or II 20-65 years old,
female patients, in this prospective, randomized, double blind study. Patients were randomly divided into two
groups and received ondansetron 8 mg (group O) or azasetron 10 mg (group A) 5 min before the end of surgery.
The incidence of PONV, Visual Analogue Scale (VAS) for pain, need for rescue antiemetic and analgesics, and
adverse effects were checked at 1, 6, 12, 24, and 48 h postoperatively. Results: The overall incidence of PONV
was 65% in group O and 49% in group A. The incidence of PONV was significantly higher in group O than in
group A at 12-24 h postoperatively (nausea; 24% vs. 45%, p = 0.035, vomiting; 2% vs. 18%, p = 0.008), but there
were no significant differences at 0-1, 1-6, 6-12 or 24-48 h. Conclusion: In conclusion, azasetron (10 mg)
produced same incidence of PONV as ondansetron (8 mg) in patients undergoing general anesthesia for
gynecological laparoscopic surgery. Azasetron was more effective, in the intermediate post-operative period,
between 12 and 24 h. 
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INTRODUCTIONaction
6 and a higher affinity to the 5HT3 receptor.
7 Azase-
tron has already been shown to be highly effective in the
prophylaxis of nausea and vomiting induced by anticancer
drugs.
8,9 However, the prophylactic effects of azasetron on
PONV is unknown.
Here, we compared the prophylactic antiemetic effect of
intravenously administered  azasetron (10 mg) and ondan-
setron (8 mg) by comparing the incidence of PONV and
the use of rescue antiemetics.
After Institutional Ethics Committee approval and informed
consent, we studied 98 patients with American Society of
Anesthesiologists physical status I or II, between the ages of
20 and 65 years, and undergoing general anesthesia for
gynecological laparoscopic surgery (total hysterectomy).
Exclusion criteria included the use of antiemetics within
24 h prior to surgery, the presence of a gastrointestinal
disease, concurrent menstruation, a history of motion
sickness, smoking, or previous PONV. No patients received
preanesthetic medication. Standard anesthetic regimens
and techniques were used for all patients. Anesthesia was
induced with propofol (2 mg/kg), and tracheal intubation
was facilitated with rocuronium 0.9 mg/kg. Anesthesia
was maintained with 66% nitrous oxide in oxygen and 2-
3% (inspired concentration) sevoflurane. All patients were
monitored with continuous ECG, blood pressure oscillome-
try, pulse oximetry and capnometry during the surgery.
End expiratory carbon dioxide was maintained at 30-35
mmHg. Arterial blood pressure and heart rate were kept
within 20% of preanesthetic values. In all patients, lactated
Ringer’s solution was administered at a rate of 8 mL/kg/
hour. A nasogastric tube was inserted so that the gastric
contents could be suctioned after anesthetic induction. At 5
min before the end of surgery, patients intravenously
received either ondansetron (Zofran
®, GlaxoSmithKline,
North Carolina, USA) 8 mg (Group O) or azasetron (Sero-
ton
®, Welfide, Co., Osaka, Japan) 10 mg (Group A), from
identical syringes. A nurse, not participating in patient
evaluation, prepared the study drugs from instructions in
numbered, sealed envelopes, assigned by random numbers
generated by a computer. At the end of surgery, patients
received pyridostigmine (15 mg) and glycopyrrolate (0.5
mg) for reversal of neuromuscular blockade. Before tra-
cheal extubation, the nasogastric tube was suctioned and
removed. For postoperative pain control, all patients receiv-
ed a bolus of nalbuphine (10 mg) at 30 min before the end
of surgery. By using the continuous balloon type infuser
(REF C0020M, Wooyoung Medical, Seoul, Korea), 50 mg
of nalbuphine and 150 mg of ketorolac, diluted in 100 mL
of 5% glucose solution, were infused continuously at 2
mL/h for 2 days. If a patient complained of pain and
requested additional analgesics, 10 mg of nalbuphine was
injected intravenously. Patients were interviewed by an
anesthesiologist (who was blind to the study drug) at 1, 6,
12, 24, and 48 h to assess nausea and vomiting. Only 2
possible answers were accepted (yes or no). Nausea was
defined as subjective sensation of discomfort associated
with the awareness of the urge to vomit. Vomiting was
defined as a forceful expulsion of gastric contents through
the mouth. PONV rescue medication (metoclopramide 10
mg IV) was delivered under the following conditions:
when nausea was intractable, three or more emetic episodes
within 15 minutes, or whenever patients requested medica-
tion. Patients who experienced nausea or vomiting at least
once during 48 h after surgery were scored positive for
PONV incidence.
Pain was recorded at 1, 6, 12, 24 and 48 h using the
Visual Analog Scale (VAS; where 0 = no pain and 10 =
worst possible pain) at rest, and the need for nalbuphine IV
was recorded. Headache and other adverse effects (i.e.,
dizziness, constipation) were also registered as present or
absent during 48 h after surgery. 
A power analysis was performed while designing the
study. Allowing an α error of 5% and β error of 20%, it
was estimated that a minimum of 42 patients per group
would be required to show a 27% difference in the incidence
of PONV.
10
Statistical analysis was performed with SPSS version 15
(Statistical Package for Social Science, SPSS Inc., Chicago,
IL, USA) to test continuous variables with an independent
t-test, and non-continuous, independent variables with
Pearson’s chi-square test and Fisher’s exact test. The values
were expressed as mean ± standard deviation or number of
patients (%). Statistical significance was set at p< 0.05. 
Patient groups did not show differences in age, body weight,
height, operation time, anesthesia time, or the amount of
infused solution (Table 1). All patients were non-smoking
females who received laparoscopic gynecological surgery
and postoperative pain control with opioid analgesics.
According to Apfel’s score,
11 these three risk factors place
them at a high risk for PONV. 
The overall incidence of PONV was 65% in group O
and 49% in group A. The incidence of nausea at 12-24 h
was significantly lower in group A than group O (24% vs.
45%, p = 0.035) (Table 2). Vomiting incidence during 12-
24 h was significantly lower in group A than in group O
(2% vs. 18%, p = 0.008) (Table 2). The need of rescue
Azasetron and Ondansetron for PONV
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MATERIALS AND METHODS
RESULTSantiemetics in 12-24 hours was lower in group A than
group O (4% vs. 18%), but not significantly. Other time
periods showed no significant differences, and there were
no differences in the number of patients that requested
rescue antiemetics (Table 2). 
VAS tended to decrease in both groups with time, with
no significant difference between the two groups. Similar
numbers of patients requested additional analgesics, and
the total amount of rescue nalbuphine was similar (150 mg
vs. 170 mg, p > 0.05). The incidence rate of adverse effects
(headache, dizziness, and constipation) was not signifi-
cantly different between two groups (Table 3). 
In the present study, ondansetron and azasetron showed
similar levels of control in overall PONV (49% vs. 65%),
however, the incidence of nausea and vomiting at 12-24 h
after surgery was significantly lower in the azasetron group.
Low-dose 5-HT3 antagonists have been shown to effecti-
vely, safely, and cost-effectively induce PONV prophylaxis
as a monotherapy at the end of anesthesia.
12-16 5-HT3
receptor antagonists selectively and competitively bind to
5-HT3 receptors, blocking serotonin binding at vagal
afferents in the gut and in the regions of the CNS involved
in emesis, including the chemoreceptor trigger zone and
the nucleus tractus solitarii.
17 However, differences in
efficacy of the 5-HT3 receptor antagonists are still unclear.
These differences may involve multiple factors such as
intrinsic differences in 5-HT3 receptor blocking activity, 5-
HT3 receptor affinity and binding stability, and differences
in autocrine activity of serotonin released from enterochro-
maffin (EC) cells to act on 5-HT3 or 5-HT4 receptors on
EC cells.
18
Ondansetron was the first member of this group to be
marketed,
19 and the recommended IV dose (4-8 mg) is
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Table 1.Demographic and Anesthesia Data 
Group O (n = 49) Group A (n = 49)
Age (yrs) 38.8 ± 8.4 39.4 ± 9.0
Weight (kg) 56.6 ± 6.0 57.1 ± 8.0
Height (cm) 157.8 ± 6.0 156.2 ± 5.5
Duration of surgery (min) 64.2 ± 25.7 62.1 ± 26.9
Duration of anesthesia (min) 92.9 ± 26.3 90.6 ± 26.3
Fluid administration (ml) 493 ± 87.8 548.9 ± 98.0
Values are mean ±SD or number of patients. 
Group O, ondansetron group; Group A, azasetron group.
Table 2. Incidence of Postoperative Nausea and Vomiting 
and Need for Rescue Antiemetics
Group O Group A
(n = 49) (n = 49)
0 - 1 hr
Nausea 6 (12) 1 (2)
Vomiting 1 (2) 0 (0)
Rescue antiemetics 1 (2) 0 (0)
1 - 6 hr
Nausea 5 (10) 8 (16)
Vomiting 1 (2) 0 (0)
Rescue antiemetics 4 (8) 5 (10)
6 - 12 hr
Nausea 16 (33) 14 (29)
Vomiting 1 (2) 2 (4)
Rescue antiemetics 5 (10) 5 (10)
12 - 24 hr
Nausea 22 (45) 12 (24)*
Vomiting 9 (18) 1 (2)
�
Rescue antiemetics 10 (18) 2 (4)
24 - 48 hr
Nausea 6 (12) 9 (18)
Vomiting 0 (0) 1 (2)
Rescue antiemetics 0 (0) 1 (2)
Overall nausea 25 (51) 21 (42)
Overall vomiting 8 (16) 5 (10)
Overall PONV 32 (65) 24 (49)
PONV, postoperative nausea and vomiting; Group O, ondansetron group; 
Group A, azasetron group.
Values are number of patient (%). 
Overall PONV, defined as the % of patients who experience nausea or
vomiting at least once during 48 h after surgery.  
*p = 0.035 vs. Group O. 
�p = 0.008 vs. Group O.
Table 3.Incidence of Adverse Effects
Group O (n = 49) Group A (n = 49)
Headache 6 (12) 4 (8)
Dizziness 3 (6) 4 (8)
Constipation 2 (4) 1 (2)
Myalgia 1 (2) 2 (4)
Values are number of patient (%) Group 
O, ondansetron group; Group A, azasetron group.
DISCUSSIONmost effective when administered just after the completion
of surgery because of its short duration of effect.
13 Its anti-
vomiting effect is stronger than its antinausea effect.
20
Haga, et al.
6 have shown that azasetron is more effective
than ondansetron on cisplatin-induced vomiting in dogs.
Fukuda, et al.
21 reported that a single bolus injection of
azasetron completely inhibited cisplatin-induced emesis
for 24 h in dogs. 
In the present study, azasetron reduced PONV for 12-24
hours significantly more than ondansetron, and tended to
reduce the need for rescue antiemetics. This difference
could result from the longer half life of azasetron, (5.4 h),
versus ondansetron (3.2 h),
6 and delayed gastric emptying
improved by azasetron.
22,23
Even with ondansetron and azasetron as prophylactic
antiemetics, most patients experienced PONV (49-65%),
perhaps because overall PONV incidence was defined as
one incident of nausea or vomiting over 48 h, or the high-
risk nature of the patients. There was no difference in risk
factors between the two groups. Continuous infusion of
nalbuphine for 48 h for postoperative pain control greatly
increases the incidence of PONV, with an incidence similar
to morphine and fentanyl.
24,25
Wu, et al.
26 reported a 46% PONV rate after ondansetron
in high risk patients who received laparoscopic gyne-
cological surgery, and Goll, et al.
27 reported a 44% PONV
rate with ondansetron in similar patients, which corres-
ponds with our PONV incidence  rates. The present study
showed that patients were still at high risk of PONV after
prophylactic treatment with ondansetron or azasetron,
suggesting that prophylactic treatment of PONV with only
5-HT3 receptor antagonists is not enough. 
As far as we are aware of, this is the first study to evaluate
the use of azasetron for PONV. The dose of ondansetron
used in this study was based on the optimal dose for pro-
phylaxis of PONV
22,28 and the dose of azasetron was based
on the standard single bolus dose for prevention of anti-
cancer agent-induced nausea and vomiting.
8,9
The present study has several limitations. When per-
forming power analysis, the expected incidence of PONV
was estimated with high risk PONV patients, not with
patients receiving identical surgery types. Also, expected
PONV reductions were not inferred from studies on same
drugs. Future studies with more patients are necessary. In
the current study, although PONV incidence in untreated
patients is unknown, we thought that it would be unethical
not to provide prophylactic therapy for high risk patients to
prevent or to reduce PONV.
In conclusion, azasetron (10 mg) produced an incidence
of PONV similar to ondansetron (8 mg) in patients under-
going general anesthesia for gynecological laparoscopic
surgery. In the intermediate post-operative period, (between
12 and 24 h), azasetron was more effective. 
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